Zobrazeno 1 - 10
of 327
pro vyhledávání: '"Kjetil Taskén"'
Autor:
Åslaug Helland, Hege G. Russnes, Gro Live Fagereng, Khalid Al-Shibli, Yvonne Andersson, Thomas Berg, Line Bjørge, Egil Blix, Bodil Bjerkehagen, Sigmund Brabrand, Marte Grønlie Cameron, Astrid Dalhaug, Dalia Dietzel, Tom Dønnem, Espen Enerly, Åsmund Flobak, Sverre Fluge, Bjørnar Gilje, Bjørn Tore Gjertsen, Bjørn Henning Grønberg, Kari Grønås, Tormod Guren, Hanne Hamre, Åse Haug, Daniel Heinrich, Geir Olav Hjortland, Eivind Hovig, Randi Hovland, Ann-Charlotte Iversen, Emiel Janssen, Jon Amund Kyte, Hedda von der Lippe Gythfeldt, Ragnhild Lothe, Jo-Åsmund Lund, Leonardo Meza-Zepeda, Monica Cheng Munthe-Kaas, Olav Toai Duc Nguyen, Pitt Niehusmann, Hilde Nilsen, Katarina Puco, Anne Hansen Ree, Tonje Bøyum Riste, Karin Semb, Eli Sihn Samdal Steinskog, Andreas Stensvold, Pål Suhrke, Øyvind Tennøe, Geir E. Tjønnfjord, Liv Jorunn Vassbotn, Eline Aas, Kristine Aasebø, Kjetil Tasken, Sigbjørn Smeland
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-2 (2022)
Externí odkaz:
https://doaj.org/article/d1675781ce0d4327ba7f57f4b202f48a
Autor:
Elisa Bjørgo, Gro L. Fagereng, Hege G. Russnes, Sigbjørn Smeland, Kjetil Taskén, Åslaug Helland
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/ccbf3147c396479db17778c1fcc62cf3
Autor:
Pilar Ayuda-Durán, Johanne U. Hermansen, Mariaserena Giliberto, Yanping Yin, Robert Hanes, Sandra Gordon, Heikki Kuusanmäki, Andrea M. Brodersen, Aram N. Andersen, Kjetil Taskén, Krister Wennerberg, Jorrit M. Enserink, Sigrid S. Skånland
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-13 (2023)
Abstract The principle of drug sensitivity testing is to expose cancer cells to a library of different drugs and measure its effects on cell viability. Recent technological advances, continuous approval of targeted therapies, and improved cell cultur
Externí odkaz:
https://doaj.org/article/0b868ee39c1047a4b864764b20e6bee8
Autor:
Kjetil Taskén, Soemeya F. Haj Mohammad, Gro Live Fagereng, Ragnhild Sørum Falk, Åslaug Helland, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Katarina Steen Carlsson, Bettina Ryll, Katriina Jalkanen, Anders Edsjö, Hege G. Russnes, Ulrik Lassen, Ebba Hallersjö Hult, Iwona Lugowska, Jean-Yves Blay, Loic Verlingue, Edvard Abel, Maeve A. Lowery, Matthew G. Krebs, Kristoffer Staal Rohrberg, Kristiina Ojamaa, Julio Oliveira, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation o
Externí odkaz:
https://doaj.org/article/a341b8825c7a4512be06dc2a4bf54da1
Autor:
Katarina Puco, Gro Live Fagereng, Sigmund Brabrand, Pitt Niehusmann, Egil Støre Blix, Eli Sihn Samdal Steinskog, Åse Haug, Cecilie Fredvik Torkildsen, Irja Alida Oppedal, Sebastian Meltzer, Åsmund Flobak, Kajsa Anna Margareta Johansson, Line Bjørge, Geir Olav Hjortland, Astrid Dalhaug, Jo-Åsmund Lund, Bjørnar Gilje, Marte Grønlie Cameron, Randi Hovland, Ragnhild S. Falk, Sigbjørn Smeland, Hege Elisabeth Giercksky Russnes, Kjetil Taskén, Åslaug Helland
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: In Norway, comprehensive molecular tumour profiling is implemented as part of the public healthcare system. A substantial number of tumours harbour potentially targetable molecular alterations. Therapy outcomes may improve if
Externí odkaz:
https://doaj.org/article/7e579b1a8041406e8bd9367ceab85308
Autor:
Ida Gregersen, Xiang Y. Kong, Sander Kooijman, Håvard Foyn, Helene Grannes, Maria B. Olsen, Anna M. Lone, Kuan Yang, Ana Quiles-Jiménez, Marianne Tran, Jonas Øgaard, Filip M. Segers, Azita Rashidi, Ellen Lund Sagen, Knut H. Lauritzen, Amanda C.M. Pronk, Jan Freark de Boer, Kirsten B. Holven, Espen Melum, Pål Aukrust, Kjetil Taskén, Sverre Holm, Patrick C.N. Rensen, Tuva B. Dahl, Bente Halvorsen
Publikováno v:
iScience, Vol 27, Iss 4, Pp 109471- (2024)
Summary: Obesity is a complex multicausal disease that can cause morbidity and mortality, and there is need for improved knowledge on the underlying mechanisms. Using a mouse model of increased T cell responsiveness, we show that development of obesi
Externí odkaz:
https://doaj.org/article/4eebcfac72e641d6a1735c3f7f6c06bf
Autor:
Johanne U. Hermansen, Yanping Yin, Aleksandra Urban, Camilla V. Myklebust, Linda Karlsen, Katrine Melvold, Anders A. Tveita, Kjetil Taskén, Ludvig A. Munthe, Geir E. Tjønnfjord, Sigrid S. Skånland
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract The microenvironment of chronic lymphocytic leukemia (CLL) cells in lymph nodes, spleen, and bone marrow provides survival, proliferation, and drug resistance signals. Therapies need to be effective in these compartments, and pre-clinical mo
Externí odkaz:
https://doaj.org/article/c9d49e1d86744257bcc85e229f404a21
Autor:
Leonardo Miranda Santana, Deepak B. Thimiri Govinda Raj, Andrea Cremaschi, Mariaserena Giliberto, Alexandra Gade, Arnoldo Frigessi, Geir E. Tjønnfjord, Ludvig A. Munthe, Sigrid S. Skånland, Manuela Zucknick, Kjetil Taskén
Publikováno v:
HemaSphere, Vol 7, p e743599b (2023)
Externí odkaz:
https://doaj.org/article/fd7ad490e30e42b99eeb8b1340c8b413
Autor:
Katrine Melvold, Mariaserena Giliberto, Linda Karlsen, Pilar Ayuda‐Durán, Robert Hanes, Toril Holien, Jorrit Enserink, Jennifer R. Brown, Geir E. Tjønnfjord, Kjetil Taskén, Sigrid S. Skånland
Publikováno v:
Molecular Oncology, Vol 16, Iss 5, Pp 1153-1170 (2022)
Most patients with chronic lymphocytic leukemia (CLL) initially respond to targeted therapies, but eventually relapse and develop resistance. Novel treatment strategies are therefore needed to improve patient outcomes. Here, we performed direct drug
Externí odkaz:
https://doaj.org/article/67352beffad14b0ba011733748ab3689
Autor:
Mariaserena Giliberto, Deepak B. Thimiri Govinda Raj, Andrea Cremaschi, Sigrid S. Skånland, Alexandra Gade, Geir E. Tjønnfjord, Fredrik Schjesvold, Ludvig A. Munthe, Kjetil Taskén
Publikováno v:
Molecular Oncology, Vol 16, Iss 6, Pp 1241-1258 (2022)
The management of multiple myeloma (MM) is challenging: An assortment of available drug combinations adds complexity to treatment selection, and treatment resistance frequently develops. Given the heterogeneous nature of MM, personalized testing tool
Externí odkaz:
https://doaj.org/article/71633b5db14044a08b75a456ac66df48